|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Study Type: | Interventional |
|---|---|
| Study Design: | Allocation: Randomized; Endpoint Classification: Efficacy Study; Intervention Model: Parallel Assignment; Masking: Open Label; Primary Purpose: Treatment |
| Condition: |
Amblyopia |
| Interventions: |
Drug: Atropine Device: Patching Procedure: Near activities |
Participant Flow
| Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations |
|---|
| Between August 2005 and July 2007, 233 subjects were randomized at 39 certified sites (193 with moderate amblyopia 20/40 to 20/100 in a primary cohort, and an additional 40 with severe amblyopia 20/125 to 20/400 that were followed as a secondary cohort). |
| Significant events and approaches for the overall study following participant enrollment, but prior to group assignment |
|---|
| Subjects must have been wearing optimal spectacle correction for a minimum of 16 weeks or until stability of visual acuity was documented (no improvement in amblyopic eye visual acuity at 2 consecutive visits at least 4 weeks apart) before enrollment and randomization. |
| Description | |
|---|---|
| Patching-Moderate Amblyopia | Patching 2 hours per day plus near activities for one hour while patching among patients with moderate amblyopia (20/40 to 20/100) |
| Atropine-Moderate Amblyopia | Atropine 1% once each weekend day in the sound eye plus near activities for at least one hour every day among patients with moderate amblyopia (20/40 to 20/100). |
| Patching-Severe Amblyopia | Patching 2 hours per day plus near activities for one hour while patching among patients with severe amblyopia (20/125 to 20/400) |
| Atropine-Severe Amblyopia | Atropine 1% once each weekend day in the sound eye plus near activities for at least one hour every day among patients with severe amblyopia (20/125 to 20/400). |
| Patching-Moderate Amblyopia | Atropine-Moderate Amblyopia | Patching-Severe Amblyopia | Atropine-Severe Amblyopia | |
|---|---|---|---|---|
| STARTED | 98 [1] | 95 [1] | 18 [2] | 22 [2] |
| 5 Week Visit | 91 | 89 | 17 | 19 |
| COMPLETED | 84 [3] | 88 [3] | 13 [3] | 20 [3] |
| NOT COMPLETED | 14 | 7 | 5 | 2 |
| [1] | Includes subjects with moderate amblyopia only (20/40 to 20/100 at baseline) |
|---|---|
| [2] | Includes subjects with severe amblyopia only (20/125 to 20/400 at baseline) |
| [3] | Completed defined as completing 17 week primary outcome exam |
Baseline Characteristics
| Description | |
|---|---|
| Patching-Moderate Amblyopia | Patching 2 hours per day plus near activities for one hour while patching among patients with moderate amblyopia (20/40 to 20/100) |
| Atropine-Moderate Amblyopia | Atropine 1% once each weekend day in the sound eye plus near activities for at least one hour every day among patients with moderate amblyopia (20/40 to 20/100). |
| Patching-Severe Amblyopia | Patching 2 hours per day plus near activities for one hour while patching among patients with severe amblyopia (20/125 to 20/400) |
| Atropine-Severe Amblyopia | Atropine 1% once each weekend day in the sound eye plus near activities for at least one hour every day among patients with severe amblyopia (20/125 to 20/400). |
| Patching-Moderate Amblyopia | Atropine-Moderate Amblyopia | Patching-Severe Amblyopia | Atropine-Severe Amblyopia | Total | |
|---|---|---|---|---|---|
|
Number of Participants
[units: participants] |
98 | 95 | 18 | 22 | 233 |
|
Age
[1] [units: years] Mean ± Standard Deviation |
8.9 ± 1.5 | 9.1 ± 1.6 | 9.5 ± 1.5 | 9.2 ± 1.8 | 9.0 ± 1.6 |
|
Age, Customized
[1] [units: participants] |
|||||
| 7 to <8 years | 35 | 28 | 6 | 9 | 78 |
| 8 to <9 years | 24 | 26 | 0 | 4 | 54 |
| 9 to <10 years | 17 | 16 | 5 | 3 | 41 |
| 10 to <11 years | 8 | 10 | 4 | 2 | 24 |
| 11 to <12 years | 8 | 7 | 2 | 1 | 18 |
| 12 to <13 years | 6 | 8 | 1 | 3 | 18 |
|
Gender
[units: participants] |
|||||
| Female | 48 | 54 | 4 | 12 | 118 |
| Male | 50 | 41 | 14 | 10 | 115 |
|
Race/Ethnicity, Customized
[units: participants] |
|||||
| White | 68 | 56 | 16 | 18 | 158 |
| African-American | 8 | 11 | 2 | 1 | 22 |
| Hispanic or Latino | 20 | 23 | 0 | 3 | 46 |
| Asian | 0 | 1 | 0 | 0 | 1 |
| More than one race | 1 | 2 | 0 | 0 | 3 |
| Not reported | 1 | 2 | 0 | 0 | 3 |
|
Cause of Amblyopia
[units: participants] |
|||||
| Strabismus | 28 | 33 | 4 | 4 | 69 |
| Anisometropia | 46 | 31 | 6 | 9 | 92 |
| Strabismus and anisometropia | 24 | 31 | 8 | 9 | 72 |
|
Distance Visual Acuity in Amblyopic Eye
[2] [units: participants] |
|||||
| 20/400 (18 to 22 letters) (worse) | 0 | 0 | 0 | 1 | 1 |
| 20/320 (23 to 27 letters) | 0 | 0 | 0 | 1 | 1 |
| 20/250 (28 to 32 letters) | 0 | 0 | 2 | 4 | 6 |
| 20/200 (33 to 37 letters) | 0 | 0 | 8 | 3 | 11 |
| 20/160 (38 to 42 letters) | 0 | 0 | 5 | 4 | 9 |
| 20/125 (43 to 47 letters) | 0 | 0 | 3 | 9 | 12 |
| 20/100 (48 to 52 letters) | 6 | 13 | 0 | 0 | 19 |
| 20/80 (53 to 57 letters) | 15 | 13 | 0 | 0 | 28 |
| 20/63 (58 to 62 letters) | 24 | 22 | 0 | 0 | 46 |
| 20/50 (63 to 67 letters) | 33 | 28 | 0 | 0 | 61 |
| 20/40 (68 to 72 letters) (best) | 20 | 19 | 0 | 0 | 39 |
|
Distance Visual Acuity in Fellow Eye
[2] [units: participants] |
|||||
| 20/32 (73 to 77 letters) (worse) | 0 | 0 | 0 | 0 | 0 |
| 20/25 (78 to 82 letters) | 17 | 20 | 1 | 6 | 44 |
| 20/20 (83 to 87 letters) | 43 | 47 | 8 | 5 | 103 |
| 20/16 (88 to 92 letters) | 36 | 26 | 9 | 11 | 82 |
| 20/12 (93 to 97 letters) (best) | 2 | 2 | 0 | 0 | 4 |
|
Prior Treatment for Amblyopia at Enrollment
[units: participants] |
|||||
| None | 71 | 68 | 13 | 18 | 170 |
| Patching | 16 | 16 | 2 | 3 | 37 |
| Atropine | 2 | 0 | 1 | 0 | 3 |
| Patching and atropine | 9 | 11 | 2 | 1 | 23 |
|
Refractive Error in Amblyopic Eye (spherical equivalent)
[3] [units: participants] |
|||||
| < 0 Diopters (D) | 2 | 2 | 0 | 0 | 4 |
| 0 to < +1.00D | 8 | 10 | 1 | 1 | 20 |
| +1.00 to < +2.00D | 13 | 6 | 2 | 2 | 23 |
| +2.00 to < +3.00D | 10 | 8 | 1 | 3 | 22 |
| +3.00 to < +4.00D | 23 | 16 | 2 | 4 | 45 |
| >= +4.00D | 42 | 53 | 12 | 12 | 119 |
|
Refractive Error in Fellow Eye (spherical equivalent)
[3] [units: participants] |
|||||
| < 0 Diopters (D) | 1 | 2 | 0 | 0 | 3 |
| 0 to < +1.00D | 32 | 29 | 4 | 9 | 74 |
| +1.00 to < +2.00D | 33 | 17 | 8 | 5 | 63 |
| +2.00 to < +3.00D | 13 | 9 | 1 | 2 | 25 |
| +3.00 to < +4.00D | 7 | 6 | 2 | 2 | 17 |
| >= +4.00D | 12 | 32 | 3 | 4 | 51 |
|
Distance Visual Acuity in Amblyopic Eye
[2] [units: ETDRS letter score] Mean ± Standard Deviation |
62.4 ± 5.7 | 61.7 ± 6.6 | 37.5 ± 5.0 | 37.5 ± 7.5 | 57.9 ± 11.1 |
|
Distance Visual Acuity in Fellow Eye
[2] [units: ETDRS letter score] Mean ± Standard Deviation |
86.0 ± 3.6 | 85.7 ± 3.4 | 87.0 ± 3.5 | 85.5 ± 4.0 | 85.9 ± 3.6 |
|
Intereye Acuity Difference
[4] [units: ETDRS letter score] Mean ± Standard Deviation |
23.5 ± 6.8 | 24.0 ± 7.0 | 49.5 ± 5.5 | 47.5 ± 9.5 | 28.0 ± 11.7 |
|
Refractive Error in Amblyopic Eye (spherical equivalent
[3] [units: diopter] Mean ± Standard Deviation |
3.57 ± 2.07 | 4.10 ± 2.19 | 4.97 ± 2.50 | 4.18 ± 1.99 | 3.95 ± 2.16 |
|
Refractive Error in Fellow Eye (spherical equivalent)
[3] [units: diopter] Mean ± Standard Deviation |
1.84 ± 1.74 | 2.56 ± 2.22 | 2.12 ± 1.76 | 1.98 ± 2.11 | 2.17 ± 2.00 |
| [1] | Age at enrollment |
|---|---|
| [2] | Visual acuity was measured in each eye using the electronic early treatment diabetic retinopathy study (E-ETDRS) method which resulted in a letter score that could range from 0 to 97 letters, with 0 being the worst and 97 being the best. |
| [3] | Measured in diopters (D) using cycloplegic refraction sphere, cylinder, and axis. Spherical equivalent is defined as the sphere plus 1/2 the cylinder. |
| [4] | Visual acuity was measured in each eye using the electronic early treatment diabetic retinopathy study (E-ETDRS) method which resulted in a letter score that could range from 0 to 97 letters, with 0 being the worst and 97 being the best. Intereye difference defined as the difference between ETDRS letter scores (amblyopic eye minus sound eye). |
Outcome Measures
| 1. Primary: | Distribution of Visual Acuity in the Amblyopic Eye at 17 Weeks [ Time Frame: 17 weeks ] |
| 2. Primary: | Mean Visual Acuity in the Amblyopic Eye at 17 Weeks [ Time Frame: 17 weeks ] |
| 3. Primary: | Distribution of Change in Visual Acuity in the Amblyopic Eye From Baseline to 17 Weeks [ Time Frame: Baseline to 17 weeks ] |
| 4. Primary: | Mean Change in Visual Acuity in the Amblyopic Eye From Baseline to 17 Weeks [ Time Frame: Baseline to 17 weeks ] |
| 5. Secondary: | Stereoacuity Measured by the Randot Preschool Test at 17 or 19 Weeks- Participants With All Causes of Moderate Amblyopia [ Time Frame: 17 or 19 weeks ] |
| 6. Secondary: | Stereoacuity Measured by the Randot Preschool Test at 17 or 19 Weeks- Anisometropic Participants With Moderate Amblyopia Only [ Time Frame: 17 or 19 weeks ] |
| 7. Secondary: | Stereoacuity Measured by the Randot Preschool Test at 17 or 19 Weeks- Participants With Moderate Amblyopia From Strabismus Only or Combined Mechanism [ Time Frame: 17 or 19 weeks ] |
| 8. Secondary: | Stereoacuity Measured by the Randot Preschool Test at 17 or 19 Weeks- Participants With All Causes of Moderate Amblyopia [ Time Frame: 17 or 19 weeks ] |
| 9. Secondary: | Amblyopia Treatment Index - Social Stigma (Moderate Amblyopia Only) [ Time Frame: 17 weeks ] |
| 10. Secondary: | Amblyopia Treatment Index - Compliance (Moderate Amblyopia Only) [ Time Frame: 17 weeks ] |
| 11. Secondary: | Amblyopia Treatment Index - Adverse Effects Scale (Moderate Amblyopia Only) [ Time Frame: 17 weeks ] |
| 12. Secondary: | Distribution of Visual Acuity in the Fellow Eye at 17 Weeks [ Time Frame: 17 weeks ] |
| 13. Secondary: | Mean Visual Acuity in the Fellow Eye at 17 Weeks [ Time Frame: 17 weeks ] |
| 14. Secondary: | Distribution of Change in Visual Acuity in the Fellow Eye From Baseline to 17 Weeks [ Time Frame: Baseline to 17 weeks ] |
| 15. Secondary: | Mean Change in Visual Acuity in the Fellow Eye From Baseline to 17 Weeks [ Time Frame: Baseline to 17 weeks ] |
More Information
| Principal Investigators are NOT employed by the organization sponsoring the study. |
| There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. |
| Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data |
|---|
| No text entered. |
| Responsible Party: | Boy W. Beck, M.D., Ph.D., Executive Director, Jaeb Center for Health Research |
| ClinicalTrials.gov Identifier: | NCT00315328 History of Changes |
| Other Study ID Numbers: | NEI-119, 2U10EY011751 |
| Study First Received: | April 14, 2006 |
| Results First Received: | September 9, 2009 |
| Last Updated: | June 6, 2011 |
| Health Authority: | United States: Federal Government; United States: Food and Drug Administration |